201 related articles for article (PubMed ID: 23269286)
1. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein.
Han S; Levoci L; Fischer P; Wang SP; Gagen K; Chen Y; Xie D; Fisher T; Ehrhardt AG; Peier AM; Johns DG
Biochim Biophys Acta; 2013 Apr; 1831(4):825-33. PubMed ID: 23269286
[TBL] [Abstract][Full Text] [Related]
2. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
[TBL] [Abstract][Full Text] [Related]
3. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
7. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
Wu BJ; Li Y; Ong KL; Sun Y; Johns D; Barter PJ; Rye KA
Sci Rep; 2019 Nov; 9(1):16183. PubMed ID: 31700015
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
9. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
[TBL] [Abstract][Full Text] [Related]
10. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
[TBL] [Abstract][Full Text] [Related]
11. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
[TBL] [Abstract][Full Text] [Related]
12. Anacetrapib: a potential new therapy for dyslipidemia.
Robinson LB; Frishman WH
Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
[TBL] [Abstract][Full Text] [Related]
13. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
Page MM; Hooper AJ; Burnett JR
Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
[TBL] [Abstract][Full Text] [Related]
14. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
Roddy TP; McLaren DG; Chen Y; Xie D; Dunn K; Kulick A; Szeto D; Forrest G; Albanese K; Donnelly M; Gai C; Gewain A; Lederman H; Jensen KK; Ai X; Vachal P; Akinsanya KO; Cleary MA; Previs SF; Dansky HM; Johns DG
Eur J Pharmacol; 2014 Oct; 740():410-6. PubMed ID: 24769414
[TBL] [Abstract][Full Text] [Related]
15. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
[TBL] [Abstract][Full Text] [Related]
16. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
17. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I
PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
[TBL] [Abstract][Full Text] [Related]
19. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
20. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
